Intercept Pharmaceuticals (NASDAQ:ICPT) Price Target Lowered to $18.00 at Robert W. Baird

Intercept Pharmaceuticals (NASDAQ:ICPT – Get Rating) had its price target decreased by Robert W. Baird from $35.00 to $18.00 in a research note issued to investors on Monday, The Fly reports.

A number of other research firms have also issued reports on ICPT. HC Wainwright lowered Intercept Pharmaceuticals from a neutral rating to a sell rating and set a $8.00 target price for the company. in a report on Monday. Needham & Company LLC lifted their price target on Intercept Pharmaceuticals from $22.00 to $26.00 and gave the stock a buy rating in a report on Friday, March 3rd. Piper Sandler lifted their price target on Intercept Pharmaceuticals from $49.00 to $54.00 and gave the stock an overweight rating in a report on Monday, April 10th. SVB Leerink lifted their price target on Intercept Pharmaceuticals from $17.00 to $18.00 and gave the stock a market perform rating in a report on Friday, March 3rd. Finally, Raymond James downgraded Intercept Pharmaceuticals from an outperform rating to a market perform rating in a report on Wednesday, May 17th. One analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Hold and an average price target of $23.27.

Intercept Pharmaceuticals Price Performance

ICPT stock opened at $9.75 on Monday. Intercept Pharmaceuticals has a 52-week low of $8.82 and a 52-week high of $21.86. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 3.32. The business has a fifty day moving average of $15.25 and a two-hundred day moving average of $15.98. The stock has a market cap of $406.48 million, a price-to-earnings ratio of 1.55 and a beta of 1.26.

Intercept Pharmaceuticals (NASDAQ:ICPT – Get Rating) last issued its quarterly earnings data on Thursday, March 2nd. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.11. The firm had revenue of $77.22 million during the quarter, compared to analyst estimates of $76.89 million. As a group, research analysts anticipate that Intercept Pharmaceuticals will post -1.75 earnings per share for the current year.

Hedge Funds Weigh In On Intercept Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Intercept Pharmaceuticals by 14.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,453 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 688 shares during the period. Fuller & Thaler Asset Management Inc. grew its holdings in shares of Intercept Pharmaceuticals by 0.5% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 164,210 shares of the biopharmaceutical company’s stock worth $2,672,000 after acquiring an additional 825 shares during the period. E Fund Management Co. Ltd. grew its holdings in shares of Intercept Pharmaceuticals by 6.2% in the 1st quarter. E Fund Management Co. Ltd. now owns 14,790 shares of the biopharmaceutical company’s stock worth $199,000 after acquiring an additional 858 shares during the period. Rhumbline Advisers grew its holdings in shares of Intercept Pharmaceuticals by 3.3% in the 1st quarter. Rhumbline Advisers now owns 34,183 shares of the biopharmaceutical company’s stock worth $459,000 after acquiring an additional 1,089 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Intercept Pharmaceuticals by 20.7% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,580 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 1,127 shares during the period. Institutional investors and hedge funds own 81.09% of the company’s stock.

Intercept Pharmaceuticals Company Profile

(Get Rating)

Intercept Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia.